Jade Biosciences, Inc. (JBIO) — Cash Flow-to-Debt Ratio
Jade Biosciences, Inc. (JBIO) has a Cash Flow-to-Debt Ratio of -1.05x as of March 2026, meaning its operating cash flow of $-24.08 Million could theoretically repay -1% of its total liabilities ($22.97 Million) in one year. See JBIO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jade Biosciences, Inc. Cash Flow-to-Debt Ratio (2020–2025)
Historical debt coverage capacity for Jade Biosciences, Inc. across 6 annual periods. Also explore Jade Biosciences, Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Jade Biosciences, Inc. (2020–2025)
Year-by-year debt coverage analysis for Jade Biosciences, Inc.. For market capitalisation and broader financial context, see Jade Biosciences, Inc. (JBIO) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.49x | $-94.69 Million | $17.26 Million | ▲ +70.0% |
| 2024 | -18.26x | $-71.20 Million | $3.90 Million | ▼ -477.8% |
| 2023 | -3.16x | $-56.78 Million | $17.96 Million | ▲ +30.9% |
| 2022 | -4.57x | $-39.12 Million | $8.56 Million | ▲ +50.9% |
| 2021 | -9.30x | $-27.40 Million | $2.94 Million | ▼ -110.0% |
| 2020 | -4.43x | $-7.86 Million | $1.77 Million | — |